| P50 | author | Penny Moore | Q55079169 |
| | Lynn Morris | Q70377150 |
| P2093 | author name string | Cynthia A. Derdeyn | |
| P2860 | cites work | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response | Q21090490 |
| | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 |
| | A Blueprint for HIV Vaccine Discovery | Q26829865 |
| | HIV-1 neutralizing antibodies: understanding nature's pathways | Q27000480 |
| | Antibodies in HIV-1 vaccine development and therapy | Q27011574 |
| | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 |
| | Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 |
| | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 |
| | Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 |
| | Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 |
| | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth | Q27676728 |
| | Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody | Q27677011 |
| | Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 |
| | Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization | Q27677117 |
| | The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies | Q27680688 |
| | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 |
| | Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 |
| | Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses | Q37718722 |
| | High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site | Q37735822 |
| | Broadly neutralizing antibodies against HIV-1: templates for a vaccine | Q38065391 |
| | Vaccine design: emerging concepts and renewed optimism | Q38087785 |
| | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies | Q43611862 |
| | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning | Q46683819 |
| | A sweet surprise for HIV broadly neutralizing antibodies | Q85389317 |
| | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways | Q33504599 |
| | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection | Q33504604 |
| | Novel directions in HIV-1 vaccines revealed from clinical trials | Q33645528 |
| | Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 |
| | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 |
| | Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual | Q33912373 |
| | Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus | Q34120140 |
| | Broadly neutralizing antiviral antibodies | Q34323311 |
| | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject | Q34478071 |
| | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter | Q34485260 |
| | Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs | Q34539819 |
| | Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial | Q34562259 |
| | Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals | Q34571277 |
| | Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity | Q34658136 |
| | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop | Q34742533 |
| | An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells | Q34796885 |
| | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes | Q35034268 |
| | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 |
| | Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses | Q35826171 |
| | Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity | Q35826458 |
| | Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design | Q35868076 |
| | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein | Q36131738 |
| | The development of CD4 binding site antibodies during HIV-1 infection | Q36155396 |
| | B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. | Q36171833 |
| | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 |
| | Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies | Q36750045 |
| | Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies | Q36760049 |
| | Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations | Q37254327 |
| | Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. | Q37318213 |
| | Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 |
| | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. | Q37360774 |
| | The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression | Q37409232 |
| | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. | Q37644030 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 210-6 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection | |
| P478 | volume | 9 | |